Search Results - "Rea, D.W"

Comparison of quadrant-specific breast cancer incidence trends in the United States and England between 1975 and 2013 by Bright, C.J, Rea, D.W, Francis, A, Feltbower, R.G

“…Highlights • In the US, breast cancer incidence has not risen at a greater rate in the UOQ compared to non-site-specific tumours. • However in England, breast…”
Get full text

Physical activity and breast cancer outcome: A brief review of evidence, current practice and future direction by Carmichael, A.R, Daley, A.J, Rea, D.W, Bowden, S.J

“…Abstract There have been several publications of large scale studies with long-term follow up addressing the role of physical activity in the management of…”
Get full text

5122 POSTER Effect of Synchronous Chemo-radiation on Quality of Life: Results From the SECRAB Trial (ISRCTN: 84214355) Presented on Behalf of the SECRAB Steering Committee by Fernando, I, Bowden, S.J, Fox, R.P, Grieve, R, Brunt, A.M, Agrawal, R.K, Ritchie, D, Simmonds, P, Bishop, J, Rea, D.W

Get full text

Synchronous Chemo-radiation Can Reduce Local Recurrence in Early Stage Breast Cancer: Results of the SECRAB Trial (ISRCTN: 84214355) Presented on Behalf of the SECRAB Steering Committee by Fernando, I, Bowden, S.J, Brookes, C.L, Grieve, R, Spooner, D, Agrawal, R.K, Brunt, A.M, Churn, M, Rea, D.W, Canney, P

Get full text

481 An indirect comparison of aromatase inhibitors (AIs) in the first line treatment of post menopausal women with hormone receptor positive (HR+) metastatic breast cancer (MBC) by Kleijnen, J, Riemsma, R, Amonkar, M.M, Lykopoulos, K, Diaz, J.R, Forbes, C.A, Rea, D.W

Get full text

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial by Bartlett, J.M.S., Sgroi, D.C., Treuner, K., Zhang, Y., Ahmed, I., Piper, T., Salunga, R., Brachtel, E.F., Pirrie, S.J., Schnabel, C.A., Rea, D.W.

“…Extending the duration of adjuvant endocrine therapy reduces the risk of recurrence in a subset of women with early-stage hormone receptor-positive (HR+)…”
Get full text

213 Duplication of chromosome 17 CEP predicts for anthracycline benefit: evidence from an international meta-analysis of 4 adjuvant breast cancer trials for the HER2/TOP2A meta-analysis study group by Bartlett, J.M.S, Munro, A, O'Malley, F.P, Earl, H, Poole, C.J, Cardoso, F, Twelves, C.J, Pritchard, K.I, Rea, D.W, Di Leo, A

Get full text

15 Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancer by Hasenburg, A, van de Velde, C.J.H, Seynaeve, C, Rea, D.W, Vannetzel, J, Paridaens, R, Markopoulos, C, Hozumi, Y, Putter, H, Jones, S.E

Get full text

11P A Breast Cancer Index (BCI) prognostic model for N0 HR+ breast cancer optimized for late distant recurrence by Bartlett, J.M.S., Zhang, Y., Ahmed, I., Treuner, K., Piper, T., Pirrie, S.J., Brufsky, A.M., Sgroi, D.C., Schnabel, C.A., Rea, D.W.

Get full text

5014 Estrogen and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational (TEAM) trial by Bartlett, J.M.S, Brookes, C.L, van de Velde, C.J.H, Billingham, L.J, Hasenberg, A, Markopoulos, C, Mallon, E.A, Paridaens, R, Seynaeve, C, Rea, D.W

Get full text

5139 Patterns of care in postmenopausal early breast cancer patients participating in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study: variations in locoregional therapy between different countries by van Nes, J.G.H, Seynaeve, C, Jones, S, Hasenburg, A, Rea, D.W, Vannetzel, J.M, Dirix, L, Markopoulos, C, Kranenbarg, W.M. Meershoek-Klein, van de Velde, C.J.H

Get full text

Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity by Fernando, I.N., Lax, S., Bowden, S.J., Ahmed, I., Steven, J.H., Churn, M., Brunt, A.M., Agrawal, R.K., Canney, P., Stevens, A., Rea, D.W.

“…SECRAB was a prospective, open-label, multicentre, randomised phase III trial comparing synchronous to sequential chemoradiotherapy (CRT). Conducted in 48 UK…”
Get full text

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer by Riemsma, Rob, Forbes, C. A, Kessels, A, Lykopoulos, K, Amonkar, M. M, Rea, D. W, Kleijnen, J

“…To undertake a systematic review of three first-line treatments (letrozole, anastrozole and exemestane) for hormone sensitive advanced or metastatic breast…”
Get full text

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer by Rea, D. W., Nortier, J. W. R., Ten Bokkel Huinink, W. W., Falk, S., Richel, D. J., Maughan, T., Groenewegen, G., Smit, J. M., Steven, N., Bakker, J. M., Semiond, D., Kerr, D. J., Punt, C. J. A.

“…Purpose:: The aim of this study was to determine in patients with previously untreated advanced colorectal cancer the maximum tolerated dose (MTD) and safety…”
Get full text

Metastatic breast cancer response after Exemestane withdrawal: a case report by Bhide, S.A., Rea, D.W.

“…A forty-three year old female patient with right sided breast cancer was treated with adjuvant radiotherapy and Tamoxifen. She had a relapse in the right…”
Get full text

Phase I intrapatient dose escalation study of weekly epirubicin and docetaxel as first line chemotherapy in metastatic breast cancer by Lo, N, Ayers, S, Catell, E, Koetz, B, Singh, N, Alexander, G, Lowe, F, Rea, D.W

Get full text

A dietary study to investigate the effects of Soya milk ingestion on steroid hormone biosynthesis in women with a high risk of developing breast cancer compared to those at normal risk by Ayers, S.J, Harris, R.M, Rea, D.W, Wood, D.M, Bottomley, L, Waring, R.H, Williamson, J, Lee, M, Kirk, C.J

Get full text

277 Combination of irinotecan and capecitabine as first line treatment in advanced colorectal cancer (ACC): results of a phase II multicenter trial by Punt, C.J.A., Nortier, J.W.R., ten Bokkel Huinink, W.W., Falk, S., Richel, D.J., Maughan, T., Groenewegen, G., Smith, J.M., Bakker, J.M., Rea, D.W.

Get full text

Site-specifically radioiodinated antibody for targeting tumors by REA, D. W, ULTEE, M. E, BELINKA, B. A, COUGHLIN, D. J, ALVAREZ, V. L

“…Labeling of an antibody site specifically through its carbohydrate regions preserves its antigen-binding activity (Rodwell et al., Proc. Natl. Acad. Sci., 83:…”
Get full text